Vivos Inc. RDGL
0.04 USD 0.00 (-2.73%)
At closeNov 9, 2026, 4:00 PM EST
0.0436 Day range 0.0447
0.0391 52-week range 0.1244
- YTD
- -37.88%
- 1 year
- -52.13%
News
globenewswire.com Vivos Inc. Announces Expansion of IsoPet® Animal Cancer Division with Four New Veterinary Clinics Across the United States Kennewick, WA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is pleased…
globenewswire.com Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and…
globenewswire.com Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities Transaction Expected to Add More…
globenewswire.com Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test Transaction Expected to Increase Stockholders' Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances Transaction Expected to Increase Stockholders' Equity; Opens Potential…
globenewswire.com Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue Vivos Management is Executing on Plan to Immediately…
globenewswire.com Vivos Therapeutics Announces Material Debt Reduction LITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and…
globenewswire.com Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology Kennewick, WA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company developing Precision Radionuclide Therapy™ (PRnT) for cancerous tumors in humans and animals,…
newsfilecorp.com Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on…
globenewswire.com Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center LITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing…
globenewswire.com Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers LITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing…
globenewswire.com Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
globenewswire.com Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India's Nuclear Regulatory Authority for International Manufacturing Center Kennewick, WA, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, today…
globenewswire.com Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update Quarter highlighted by steadily increasing patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo.,…
globenewswire.com Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing…
globenewswire.com Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology LITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing…
globenewswire.com Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy, is pleased to share this update on the meaningful…
globenewswire.com Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™, is pleased to share this update on the meaningful…
globenewswire.com Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™ Kennewick, WA, July 06, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) for the treatment of cancerous tumors, is pleased…
benzinga.com Pineapple Financial And 1 Other Stock Under $1 Insiders Are Buying 
benzinga.com Alset And 2 Other Stocks Under $2 Insiders Are Buying